Genetic polymorphism of the hepatic cytochrome p450 2C19 in North Indian subjects

Clinical Pharmacology and Therapeutics

Volumn 63, Issue 4, 1998, Pages 422-427

  Lamba, Jatinder K ^a,b   Dhiman, Radha K ^a   Kohli, Krishan K ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b INDIAN COUNCIL OF MEDICAL RESEARCH   (India)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYOMEPRAZOLE; CYTOCHROME P450 ISOENZYME; DRUG METABOLITE; LOMAC; OMEPRAZOLE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN EXPERIMENT; INDIA; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; VOLUNTEER;

ADULT; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; HYDROXYLATION; INDIA; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OMEPRAZOLE; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 0031949327     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(98)90037-6     Document Type: Article

References (22)

1. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquin/sparteine metabolism: clinical aspects. Pharmacol Ther 1990;46:377-94.
2. Balian JD, Sukhova N, Harris JW, Hewett J, Pickle L, Goldstein JA, et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clin Pharmacol Ther 1995;57:662-9.
3. Sohn DR, Kwon JT, Kim HK. Influence of S-mephenytoin phenotype on the lansoprazole metabolism [abstract]. Clin Pharmacol Ther 1996;59:137.
4. Tanaka M, OhKubo T, Otani K, Suzuki A, Kaneko S, Sugawara K, et al. Metabolic disposition of pantoprazole in Japanese subjects: relation to S-mephenytoin phenotype [abstract]. Clin Pharmacol Ther 1997;61:223.
5. Gram LF, Guentert TW, Grange S, Vistisen K, Brøsen K. Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: a panel study. Clin Pharmacol Ther 1995;57:670-7.
6. Setiabudy R, Chiba K, Kusuka M, Ishizaki T. Caution in the use of 100 mg of racemic mephenytoin for phenotyping Southeastern Oriental subjects. Br J Clin Pharmacol 1992;33:665-6.
7. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76.
8. Kaisary A, Smith P, Jacqz E, McAllister CB, Wilkinson GR, Ray WA, et al. Genetic predisposition to bladder cancer: ability to hydroxylate debrisoquine and mephenytoin as risk factors. Cancer Res 1987;47:5488-93.
9. Bertilsson L, Henthorn TK, Sanz E, Tybring G, Sawe J, Villen T. Importance of genetic factors in the regulation of diazepam metabolism: relationship to S-mephenytoin, but not debrisoquin, hydroxylation phenotype. Clin Pharmacol Ther 1989;45:348-55.
10. Hadidi HF, Irshaid YM, Woosley RL, Idle JR, Flockhart DA. S-Mephenytoin hydroxylation phenotypes in a Jordanian population. Clin Pharmacol Ther 1995;58:542-7.
11. Marinac JS, Balian JD, Foxworth JW, Willsie SK, Daus JC, Owen R, et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: Correlation with genotype. Clin Pharmacol Ther 1996;60:138-44.
12. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe. Clin Pharmacol Ther 1995;57:656-61.
13. Weerasuriya K, Jayakody RL, Smith CAD, Wolf CR, Tucker GT, Lennard MS. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study. Br J Clin Pharmacol 1994;38:466-70.
14. Doshi BS, Kulkarni RD, Chauhan BL, Wilkinson GR. Frequency of impaired mephenytoin 4′-hydroxylation in an Indian population. Br J Clin Pharmacol 1990;30:779-80.
15. Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L. Slow omeprazole metabolizers are also poor S-mephenytoin hydroxylators. Ther Drug Monit 1990;12:415-6.
16. Sohn DR, Kobayashi K, Chiba K, Lee KH, Shin SH, Ishizaki T. Disposition kinetics of metabolism of omeprazole in extensive and poor metabolizers of S-mephenytoin 4′-hydroxylation recruited from an Oriental population. J Pharmacol Exp Ther 1992;262:1195-202.
17. Kobayashi K, Chiba K, Sohn DR, Kato Y, Ishizaki T. Simultaneous determination of omeprazole and its metabolites in plasma and urine by reversed phase high performance liquid chromatography with an alkaline resistant polymer coated C18 column. J Chromatogr 1992;579:299-305.
18. Endrenyi L, Patel M. A new, sensitive graphical method for detecting deviations from the normal distribution of drug responses: the NTV plot. Br J Clin Pharmacol 1991;32:159-66.
19. Emery AEH, Mueller RF. Elements of medical genetics. 8th ed. Edinburgh: Churchill Livingstone, 1992. p. 241-64.
20. de Morais SMF, Goldstein JA, Xie HG, Huang SL, Lu YQ, Xia H, et al. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population. Clin Pharmacol Ther 1995;58:404-11.
21. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
22. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.